Literature DB >> 23566254

Transmembrane mucin MUC1 overexpression and its association with CD10⁺ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer.

Do Trong Khanh1, Eiji Mekata, Ken-ichi Mukaisho, Hiroyuki Sugihara, Tomoharu Shimizu, Hisanori Shiomi, Satoshi Murata, Shigeyuki Naka, Hiroshi Yamamoto, Yoshihiro Endo, Tohru Tani.   

Abstract

The prognostic value of mucin expression has been reported in several studies. We examined the association between mucin expression and other previously reported prognostic factors, including infiltration of CD10⁺ myeloid cells, transforming growth factor-β1 (TGF-β1) expression, and tumor budding at invasion fronts. Immunohistochemical analysis of 206 colorectal samples was carried out to determine whether MUC1, MUC2, MUC4, and MUC5AC expression could predict the survival of colorectal cancer patients. Serial sections were stained for CD10, TGF-β1, and pan-cytokeratin in order to detect tumor budding. As per multivariate analyses, MUC1 expression appeared to be the most significant predictor of both recurrence-free survival and overall survival. MUC4 was only significant to predict recurrence-free survival, and MUC5AC could be a good marker in stage IV colorectal cancers that require additional chemotherapy. MUC1 (CD227) expression was associated with infiltration of CD10⁺ myeloid cells, TGF-β1 expression, and tumor budding grade. These findings suggest that MUC1 is indicative of poor prognoses that may be associated with immunosuppression and epithelial-mesenchymal transition. Furthermore, MUC1 expression appears to be a chemoattractant for CD10⁺ stromal cells.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566254      PMCID: PMC7657147          DOI: 10.1111/cas.12170

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  32 in total

1.  Optimal colorectal cancer staging criteria in TNM classification.

Authors:  Hideki Ueno; Hidetaka Mochizuki; Yoshito Akagi; Takaya Kusumi; Kazutaka Yamada; Masahiro Ikegami; Hiroshi Kawachi; Shingo Kameoka; Yasuo Ohkura; Tadahiko Masaki; Ryoji Kushima; Keiichi Takahashi; Yoichi Ajioka; Kazuo Hase; Atsushi Ochiai; Ryo Wada; Keiichi Iwaya; Hideyuki Shimazaki; Takahiro Nakamura; Kenichi Sugihara
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

2.  Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma.

Authors:  Xiao-Dong Bu; Nan Li; Xiao-Qiang Tian; Li Li; Jin-Song Wang; Xiao-Jin Yu; Pei-Lin Huang
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

3.  Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma.

Authors:  Haeyoun Kang; Byung Soh Min; Kang Young Lee; Nam Kyu Kim; Soo Nyung Kim; Junjeong Choi; Hoguen Kim
Journal:  Ann Surg Oncol       Date:  2010-09-24       Impact factor: 5.344

4.  Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma.

Authors:  S E Baldus; S P Mönig; F-G Hanisch; T K Zirbes; U Flucke; S Oelert; G Zilkens; B Madejczik; J Thiele; P M Schneider; A H Hölscher; H P Dienes
Journal:  Histopathology       Date:  2002-05       Impact factor: 5.087

5.  Expression of MUC5AC in colorectal carcinoma and relationship with prognosis.

Authors:  Belma Kocer; Atilla Soran; Sibel Erdogan; Melih Karabeyoglu; Osman Yildirim; Abdullah Eroglu; Betül Bozkurt; Omer Cengiz
Journal:  Pathol Int       Date:  2002-07       Impact factor: 2.534

Review 6.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

7.  Transmembrane mucin MUC1 overexpression and its association with CD10⁺ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer.

Authors:  Do Trong Khanh; Eiji Mekata; Ken-ichi Mukaisho; Hiroyuki Sugihara; Tomoharu Shimizu; Hisanori Shiomi; Satoshi Murata; Shigeyuki Naka; Hiroshi Yamamoto; Yoshihiro Endo; Tohru Tani
Journal:  Cancer Sci       Date:  2013-05-21       Impact factor: 6.716

Review 8.  The polarization of immune cells in the tumour environment by TGFbeta.

Authors:  Richard A Flavell; Shomyseh Sanjabi; Stephen H Wrzesinski; Paula Licona-Limón
Journal:  Nat Rev Immunol       Date:  2010-07-09       Impact factor: 53.106

9.  The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.

Authors:  Timothy J Duncan; Nicholas F S Watson; Ahmad H Al-Attar; John H Scholefield; Lindy G Durrant
Journal:  World J Surg Oncol       Date:  2007-03-09       Impact factor: 2.754

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  17 in total

1.  A novel mouse model of sporadic colon cancer induced by combination of conditional Apc genes and chemical carcinogen in the absence of Cre recombinase.

Authors:  Jeffrey S Souris; Hannah J Zhang; Urszula Dougherty; Nai-Tzu Chen; Joseph V Waller; Leu-Wei Lo; John Hart; Chin-Tu Chen; Marc Bissonnette
Journal:  Carcinogenesis       Date:  2019-11-25       Impact factor: 4.944

Review 2.  Clinicopathological and prognostic significance of MUC4 expression in cancers: evidence from meta-analysis.

Authors:  Xing Huang; Xin Wang; Shi-Ming Lu; Chen Chen; Jie Wang; Yan-Yan Zheng; Bin-Hui Ren; Lin Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Transmembrane mucin MUC1 overexpression and its association with CD10⁺ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer.

Authors:  Do Trong Khanh; Eiji Mekata; Ken-ichi Mukaisho; Hiroyuki Sugihara; Tomoharu Shimizu; Hisanori Shiomi; Satoshi Murata; Shigeyuki Naka; Hiroshi Yamamoto; Yoshihiro Endo; Tohru Tani
Journal:  Cancer Sci       Date:  2013-05-21       Impact factor: 6.716

4.  Activation of Immune and Defense Responses in the Intestinal Mucosa by Outer Membrane Vesicles of Commensal and Probiotic Escherichia coli Strains.

Authors:  María José Fábrega; Laura Aguilera; Rosa Giménez; Encarna Varela; María Alexandra Cañas; María Antolín; Josefa Badía; Laura Baldomà
Journal:  Front Microbiol       Date:  2016-05-11       Impact factor: 5.640

5.  Prognostic Role of Mucin Antigen MUC4 for Cholangiocarcinoma: A Meta-Analysis.

Authors:  Bingmin Li; Haowen Tang; Aiqun Zhang; Jiahong Dong
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

6.  MUC4 is negatively regulated through the Wnt/β-catenin pathway via the Notch effector Hath1 in colorectal cancer.

Authors:  Muzafar A Macha; Asif Khurshid Qazi; Seema Chugh; Moorthy P Ponnusamy; Priya Pai; Satyanarayana Rachagani; Punita Dhawan; Yuri M Sheinin; Kavita Mallya; Ramesh Pothuraju; Surinder K Batra
Journal:  Genes Cancer       Date:  2016-05

7.  Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.

Authors:  Tao Fu; Yanliang Liu; Kai Li; Weiwei Wan; Emmanouil P Pappou; Christine A Iacobuzio-Donahue; Zachary Kerner; Stephen B Baylin; Christopher L Wolfgang; Nita Ahuja
Journal:  Oncotarget       Date:  2016-12-27

Review 8.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.

Authors:  Divya Thomas; Ashok Kumar Rathinavel; Prakash Radhakrishnan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-11-04       Impact factor: 10.680

9.  MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance.

Authors:  Johannes Betge; Nora I Schneider; Lars Harbaum; Marion J Pollheimer; Richard A Lindtner; Peter Kornprat; Matthias P Ebert; Cord Langner
Journal:  Virchows Arch       Date:  2016-09       Impact factor: 4.064

Review 10.  Prognostic Significance of Mucin Antigen MUC1 in Various Human Epithelial Cancers: A Meta-Analysis.

Authors:  Feng Xu; Fuquan Liu; Hongwei Zhao; Guangyu An; Guosheng Feng
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.